Adicet Bio Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) On January 22, 2024, Chen Schor, our President and Chief Executive Officer, terminated a trading plan pursuant to Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Mr. Schor’s Rule 10b5-1 trading plan, adopted on September 27, 2023, provided for the sale from time to time of a maximum of 28,500 shares of our common stock pursuant to the terms of the plan. If Mr. Schor’s Rule 10b5-1 trading plan had not been terminated, it would have expired on September 7, 2025, or earlier if all transactions under the trading arrangement were completed. The trading arrangement is intended to satisfy the affirmative defense in Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.